UroToday.com - In the October 1, 2008 issue of Clinical Cancer Research, Dr. Johann de Bono and colleagues presented exciting data indicating that circulating tumor cells (CTC) predict overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). CTC using the commercially available CellSearch is approved by the FDA as a prognostic indicator for patients with metastatic breast, prostate, and colorectal cancer. Read more ...
Radiological health expert Daniel Hayes, Ph.D., of the New York City Department of Health and Mental Hygiene suggests that a form of vitamin D could be one of our body's main protections against damage from low levels of radiation. Writing in the International Journal of Low Radiation, Hayes explains that calcitriol, the active form of vitamin D, may protect us from background radiation and could be used as a safe protective agent before or after a low-level nuclear incident. Read more ...
Over 520 guests reached into their pockets to the tune of over $1.15 million and cast their vote for increased funding for lymphoma-focused research at Vote For A Cure: the Lymphoma Research Foundation's (LRF) 2008 National Gala held on October 6 at the New York Marriot Marquis. Tom Brokaw, NBC News, shared emcee duties with Jeff Greenfield of CBS News for this very successful event. Read more ...
DxS, a personalised medicine company and market leaders in the provision of companion diagnostics are pleased to announce the addition of a PI3K Mutation Detection Kit to their portfolio of oncogene mutation products. PI3K is a biomarker assessed during the evaluation of the tyrosine kinase inhibitors targeting the EGFR pathway. The PI3K-AKT pathway is activated in a variety of tumour types resulting in cell growth and proliferation. Read more ...
Radical improvements in outcome for many cancer sufferers are in prospect following one of the most significant advances in radiotherapy since x-rays were first used to treat a tumour in 1904. The use of charged particles as an alternative to x-ray or gamma ray radiation can extend the scope of radiotherapy to tumours previously requiring invasive surgery, while speeding up diagnosis and reducing collateral damage to surrounding tissue. Read more ...
UroToday.com - Our single center study on robotic partial nephrectomy represents one of the largest series in the world. The study, which shows results comparable, if not better, than most laparoscopic series, is significant for the relatively short ischemic times and excellent pathological outcomes. Ultimately, the goal of robotic partial nephrectomy is similar to the open counterpart: to provide excellent cancer control with preservation of long term renal functional outcomes. Read more ...
DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI) today announced the launch of BCtect(TM), a blood-based test for early detection of breast cancer. The test searches for a unique gene expression signature identified by DiaGenic using a custom TaqMan(R) Array manufactured for DiaGenic by Applied Biosystems. India was chosen as the first country for the introduction of BCtect(TM) after successful completion of a large study in the country. Read more ...
Dense networks of blood vessels thought to spur cancer's growth could actually hinder rather than promote tumor progression, according to a new study at the University of California, San Diego. The findings partly explain why drugs designed to treat cancer by strangling its blood supply have been disappointing when used alone and why those treatments are more effective when combined with traditional chemotherapy. Read more ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment